Cilostazol in patients with ischemic stroke

被引：7
作者：
Al-Qudah, Zaid A. [1 ]
Hassan, Ameer E. [1 ]
Qureshi, Adnan I. [1 ]
机构：
[1] Univ Minnesota, Zeenat Qureshi Stroke Res Ctr, Dept Neurol, Minneapolis, MN 55455 USA
来源：
EXPERT OPINION ON PHARMACOTHERAPY | 2011年 / 12卷 / 08期
关键词：
acute ischemic stroke; cilostazol; neurointerventional procedures; FOCAL CEREBRAL-ISCHEMIA; DOUBLE-BLIND; TRIAL; ASPIRIN; DAMAGE; TICLOPIDINE; CLOPIDOGREL; ADENOSINE; EVENTS; RISK;
D O I：
10.1517/14656566.2011.576248
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Introduction: Several antiplatelets have been used in the prevention of secondary ischemic strokes with limited success and some carried a high risk of bleeding. Cilostazol is a relatively new antiplatelet that has been thoroughly investigated in Japan with promising outcome in secondary stroke prevention. Areas covered: In this paper, the findings of major clinical trials and the efficacy of cilostazol in preventing ischemic stroke in comparison with other more commonly used antiplatelet medications like aspirin and clopidogrel are summarized. Pharmacology and mechanism of action are also discussed. Expert opinion: Cilostazol is a safe and effective medication. It has an antiplatelet, antithrombotic and vascular endothelial proliferation inhibitory effect that makes it an excellent, promising drug for the prevention of secondary ischemic stroke and poststent thrombosis.
引用
收藏
页码：1305 / 1315
页数：11
相关论文
共 29 条
  • [1] [Anonymous], NME DRUG NEW BIOL AP
  • [2] Cojocaru Inimoara Mihaela, 2010, Rom J Intern Med, V48, P101
  • [3] RACTS: A prospective randomized antiplatelet trial of cilostazol versus ticlopidine in patients undergoing coronary stenting long-term clinical and angiographic outcome - Long-term clinical and angiographic outcome
    Ge, JB
    Han, YL
    Jiang, H
    Sun, BG
    Chen, JY
    Zhang, SY
    Du, ZM
    [J]. JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2005, 46 (02) : 162 - 166
  • [4] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)
    Gent, M
    Beaumont, D
    Blanchard, J
    Bousser, MG
    Coffman, J
    Easton, JD
    Hampton, JR
    Harker, LA
    Janzon, L
    Kusmierek, JJE
    Panak, E
    Roberts, RS
    Shannon, JS
    Sicurella, J
    Tognoni, G
    Topol, EJ
    Verstraete, M
    Warlow, C
    [J]. LANCET, 1996, 348 (9038) : 1329 - 1339
  • [5] Cilostazol: Potential mechanism of action for antithrombotic effects accompanied by a low rate of bleeding
    Goto, Shinya
    [J]. ATHEROSCLEROSIS SUPPLEMENTS, 2005, 6 (04) : 3 - 11
  • [6] GOTOH HTF, 2000, J STROKE CEREBROVASC, V9, P147
  • [7] Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled study
    Han, Yaling
    Li, Yi
    Wang, Shouli
    Jing, Quanmin
    Wang, Zhulu
    Wang, Dongmei
    Shu, Qingfen
    Tang, Xiuying
    [J]. AMERICAN HEART JOURNAL, 2009, 157 (04) : 733 - 739
  • [8] Antithrombotic drugs for patients with ischaemic stroke and transient ischaemic attack to prevent recurrent major vascular events
    Hankey, Graeme J.
    Eikelboom, John W.
    [J]. LANCET NEUROLOGY, 2010, 9 (03) : 273 - 284
  • [9] A RANDOMIZED TRIAL COMPARING TICLOPIDINE HYDROCHLORIDE WITH ASPIRIN FOR THE PREVENTION OF STROKE IN HIGH-RISK PATIENTS
    HASS, WK
    EASTON, JD
    ADAMS, HP
    PRYSEPHILLIPS, W
    MOLONY, BA
    ANDERSON, S
    KAMM, B
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1989, 321 (08) : 501 - 507
  • [10] Characterization of human cytochrome p450 enzymes involved in the metabolism of cilostazol
    Hiratsuka, Masahiro
    Hinai, Yudai
    Sasaki, Takamitsu
    Konno, Yumiko
    Imagawa, Kenichi
    Ishikawa, Masaaki
    Mizugaki, Michinao
    [J]. DRUG METABOLISM AND DISPOSITION, 2007, 35 (10) : 1730 - 1732
123